D

Dana-Farber Cancer Institute

Cancer treatment and research institute

Regulatory Coordinator - Lymphoma

Full-Time
$55.5k - $61.7k
Entry
Bachelor's
Boston, MA, USA
RemoteRemote work is limited to New England states (ME, VT, NH, MA, CT, RI), with occasional on-campus time in Boston.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • The position requires a bachelor's degree or one year of experience as a Dana-Farber Associate Regulatory Coordinator.
  • Must be able to perform the day-to-day responsibilities with regular and ongoing training and supervision.
  • Must attain and demonstrate fundamental knowledge and some proficiency in DFCI, DF/HCC, ICH/GCP, and FDA policy, guidance, and regulation; the IRB submission and approval process; Regulatory Binder maintenance; PI-initiated and multi-center trials; protocol and consent design and development; and FDA IND and other required regulatory submissions.
  • Must possess written and oral communication skills, maintain confidentiality, demonstrate good decision-making and judgment, and have attention to detail and follow-through skills.
  • Must have organization and time management/prioritization skills and the ability to work independently.
  • Must be proficient in computers, Microsoft applications, and databases.
  • Requires experience with medical terminology.
Responsibilities
  • Prepare and submit protocol applications, amendments, continuing reviews, and informed consent documents for SRC and IRB review and approval.
  • Prepare and submit regulatory documentation, including IND/IDE applications, FDA annual reports, and Serious Adverse Event reports, to appropriate regulatory agencies including the FDA and OBA.
  • Prepare, maintain, and organize regulatory files for each assigned study in compliance with study sponsor requirements.
  • Maintain regulatory tracking databases with information related to study recruitment, subject enrollment, and study progress and completion.
  • Assist in preparing and coordinating assigned study monitoring and auditing visits with the study coordinator, investigator, DF/HCC ODQ, industry sponsors, and third-party auditors.
  • Track and manage assigned new-protocol start-up packets; initiate, facilitate, and monitor study start-up progress to ensure established benchmarks are met.
  • Communicate and collaborate with clinical trial stakeholders through the start-up process, provide regular updates, and ensure start-up activities are completed.
  • Create and maintain tracking for subsequent SRC/IRB submissions, including protocol and consent amendments, safety reporting, deviation, violation, exception, and other event reporting; ensure required reporting to sponsors, the FDA, and IRB is completed.
  • Enter subject visit tracking information, as applicable, into the Clinical Trial Management System contemporaneously with medical visits, assessments, and other subject-specific information.
  • Enter time and effort spent on study-specific activities and other administrative tasks into the Clinical Trial Management System contemporaneously with work completed.
  • Enter study-specific activity, including monitor visits, external site enrollment, amendments, and receipt of safety reports, into the Clinical Trial Management System contemporaneously with activity completed.
  • Establish and maintain regular communication with the study team, sponsor, and applicable regulatory agencies or offices; relay required information and systematically document and track it when applicable.
  • Facilitate communication between the study team and sponsor regarding study status, critical safety issues, upcoming protocol, consent and IDB amendments, and applicable protocol training; systematically document and track information when applicable.
  • Maintain working knowledge of current regulations, regulatory guidance, and local policies.
  • Assist the Clinical Research Manager with regulatory-based training and implementation of new or revised regulations, guidance, and local policies.
  • Present regulatory status for the disease group portfolio at applicable research meetings.
Desired Qualifications
  • 0–1 years of experience in a medical, scientific research, or technology-oriented business environment, along with a basic understanding of clinical trial conduct.

About the company

D

Dana-Farber Cancer Institute

View
Website

Dana-Farber Cancer Institute provides cancer treatment and research services in Boston, serving both adult and pediatric patients. It combines patient care with a broad program of clinical trials and basic, translational, and collaborative research to advance cancer treatments. Treatments include personalized care and access to more than 700 clinical trials, aiming to tailor therapies to the patient’s tumor profile and disease type, often through targeted therapies, immunotherapy, chemotherapy, radiation, and surgical options offered at multiple treatment centers and satellite sites. The Institute differentiates itself through its affiliation with Harvard Medical School and Brigham and Women’s Hospital, its long history of cancer research breakthroughs, nationwide and international reach, and the Jimmy Fund to support patients and research. Its goal is to defeat cancer by delivering expert care while rapidly translating research discoveries into new treatments for patients everywhere.

Company Size

5,001-10,000

Company Stage

Grant

Total Funding

$54.9M

Headquarters

Boston, Massachusetts

Founded

1947

Get referred to Dana-Farber Cancer Institute

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 2026-09 outpatient Brighton clinic adds 65 exam rooms and 83 infusion chairs.
  • 2026-08-26 $35 million Lubin gift funds construction, research, and patient support.
  • 2026-09-15 Dana-Farber/Boston Children's ranked the nation's top pediatric cancer program again.

What critics are saying

  • 2025-12-16 DOJ settlement forced Dana-Farber to pay $15 million for research fraud.
  • Mass General Brigham is building a rival cancer institute and unwinding Dana-Farber ties by 2028.
  • Physician assistant turmoil in 2026 exposed fragile staffing during the Brigham transition.

What makes Dana-Farber Cancer Institute unique

  • 2026-09-14 DESTINY-Lung04 showed Dana-Farber setting first-line HER2-mutant NSCLC standard.
  • 2026-09-10 Solavia embeds Dana-Farber oncology pathways into oncologists' electronic workflows.
  • Lavine Bekenstein Cancer Hospital, opening 2031, extends Dana-Farber's inpatient and ambulatory control.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

16%

1 year growth

16%

2 year growth

16%
Beth Israel Deaconess Medical Center
Oct 16th, 2026
BIDMC and Dana-Farber bring new care model and treatment advances to breast cancer patients as part of collaboration.

BIDMC and Dana-Farber bring new care model and treatment advances to breast cancer patients as part of collaboration. October 16, 2026 BOSTON - Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber Cancer Institute announced that on October 19, clinical services for breast oncology will fully transition to a new model that delivers outstanding multidisciplinary care as part of a clinical collaboration between the two hospitals. Outpatient breast oncology services will be provided at Dana-Farber, home to the largest clinical breast cancer program in New England, while breast cancer surgical services will be provided by a renowned team of surgeons at BIDMC from Harvard Medical Faculty Physicians at BIDMC (HMFP). Breast oncology is the first treatment center to transition as part of a phased approach that will happen over the next several years. The surgical team is led by Elizabeth Mittendorf, MD, PhD, MHCM, Chief of the Division of Breast Surgery at BIDMC; chief of Multi-Disciplinary Oncology at Dana-Farber; and co-leader of the Breast Program for the Harvard Cancer Consortium. Mittendorf also serves as President of the American Society of Clinical Oncology (ASCO), a role in which she helps shape and inform oncology care across the country. She is internationally recognized as a groundbreaking innovator in immunotherapy for breast cancer. Previously, Mittendorf was the Rob and Karen Hale Endowed Chair of Surgical Oncology at Brigham and Women's Hospital. "I've had the privilege of working side-by-side with this team of breast surgeons and can confidently say they are among the best in the world - passionate about delivering the best possible care for our patients while also collaborating with our multi-disciplinary colleagues to drive clinical excellence and future innovations in breast cancer care," said Mittendorf. "Our new care model allows us to deliver extraordinary, highly personalized care to patients while pushing the boundaries of innovation in cancer research." More personalized care with AI mammography. BIDMC was the first hospital in the country to offer Clairity Breast, the first FDA-authorized artificial intelligence software that analyzes a woman's routine mammogram to help determine whether they are at risk of developing breast cancer in the future. Clairity Breast supplements the standard screening mammogram to generate an individual's five-year risk of developing breast cancer. "Incorporating Clairity is part of our broader breast cancer screening effort to make risk assessments more accessible," said Mittendorf. "We are the first hospital in the country to offer this service, which will hopefully allow us to find breast cancers in the earliest and most treatable stages, and deliver more personalized screenings for women." To date, 125 women have utilized the Clairity screening tool at BIDMC with 550 additional screening appointments scheduled in the coming months. Largest portfolio of Breast cancer clinical trials continues to grow. Dana-Farber is home to the largest portfolio of breast cancer clinical trials in New England. These scientific studies are designed to evaluate new and promising treatments - including drugs, diagnostic procedures, and other therapies - in patients to help determine their safety and effectiveness. Nearly all cancer drugs in use today have undergone testing in clinical trials. "Clinical trials are the bedrock of cancer research, helping to advance new medicines and further improve care practices," said Sara Tolaney, MD, MPH, Chief of Breast Oncology at Dana-Farber Cancer Institute. "Importantly, clinical trials also give our patients the opportunity to benefit from new and potentially groundbreaking therapies, in many instances, long before they are approved by the FDA. We are proud to offer a large and growing portfolio of clinical trials for every type of breast cancer so that our patients have access to the best possible medicines and practices." Clinical trials are available at Dana-Farber for every type of breast cancer - from early-stage to metastatic disease, as well as rare subtypes such as male breast cancer and inflammatory breast cancer. Surgical clinical trials are also available at BIDMC to help alleviate lymphedema, improve breast reconstruction, advance less invasive surgical techniques and enhance quality of life. In just the past year, three new breast cancer therapies have been approved by the FDA based on Dana-Farber-led clinical studies which have set a new standard of care for HER2+ metastatic breast cancer, triple-negative metastatic breast cancer and hormone-receptor positive breast cancer. Multidisciplinary, patient-centered care. "Breast cancer is not one disease, but rather a series of very specific subtypes that require different therapies and approaches, each tailored to the individual patient," said Mittendorf. "As surgeons at BIDMC, we are working hand-in-glove with our colleagues in breast oncology at Dana-Farber, and radiation oncology, pathology, reconstructive surgery, and across other disciplines to deliver the best possible care and outcomes for our patients." Beyond expert surgical and clinical care, breast cancer patients at Dana-Farber and BIDMC have access to fertility preservation services to help women undergoing cancer treatment preserve their ability to start a family, psychosocial support, genetic testing to inform future cancer risk and guide treatment decisions, expert geriatric care, and complementary therapies to ease treatment-related symptoms. Dana-Farber has also established leading evidenced-based programs and centers of excellence to support patients with specific breast cancer types such as Young and Strong which offers tailored support for the unique needs of young women with breast cancer, EMBRACE for patients living with metastatic breast cancer, the program for older adults with breast cancer, among many others specialties. Meanwhile, BIDMC is home to the Boston Lymphatic Center which provides leading care for patients effected by lymphedema, a common and difficult breast cancer side effect, as well as Comprehensive Breast Care Center which offers multidisciplinary, comprehensive risk assessment, surveillance and prevention program for women known to be at increased risk and for those interested in learning about their risk for breast cancer. "No two patients are exactly alike, which is why we design our therapies and support programs for each individual we care for," said Tolaney. "We are excited to offer our patients an even broader portfolio of resources and expert care through our collaboration with our colleagues at BIDMC and to further grow our personalized breast cancer care model." About Beth Israel Deaconess Medical Center. Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education. Director, Media Relations Sarah finlaw. Please note: The contact information above is for journalists and news media only. For patient care and all other inquiries, please contact your doctor or hospital directly.

Automotive Press Releases
Oct 15th, 2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal.

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal. * Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors * Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites * APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade >=3 treatment-related adverse events * Disease stabilization was observed in 5 of 10 RECIST-evaluable patients Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - invIOs GmbH ("invIOs"), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, "Phase I Evaluation of APN401, an Autologous CBL-B-Silenced PBMC Therapy, in Advanced Solid Tumors", reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors. A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade >=3 treatment-related adverse events. The highest dose of 4.5 x 10[7] PBMCs/kg was selected as the recommended Phase 2 dose. Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit. APN401 is an autologous cell therapy utilizing patients' own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells. Romana Gugenberger, PhD, Managing Director of invIOs, commented: "We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors." APN401 is produced using invIOs' proprietary EPiC(R) point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration. About invIOs invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs' proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient's fresh immune cells, enabling rapid treatment in an out-patient setting. The platform's lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types. INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications. For further information, please visit www.invios.com and connect with us on LinkedIn.Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - | invIOs Romana Gugenberger, PhD Managing Director T +43 1 8656577 0 Email: [email protected] | MC Services AG Dr. Cora Kaiser, Dr. Regina Lutz T +49 89 210 228 0 US: Laurie Doyle T +1-339-832-0752 Email: [email protected] | Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Dana-Farber Cancer Institute
Oct 9th, 2026
Joyce Liu wins prestigious award from the National Cancer Institute.

Joyce Liu wins prestigious award from the National Cancer Institute. Posted date October 9, 2026 Joyce Liu, MD, MPH of Dana-Farber Cancer Institute is the recipient of the 2026 Michaele C. Christian Oncology Drug Development Award and Lectureship from the National Cancer Institute (NCI). The prestigious honor awarded annually recognizes individuals who have made significant contributions to the development of novel investigational agents for cancer therapy. Liu serves as associate chief and clinical research director of the Division of Gynecologic Oncology at Dana-Farber. In these roles, Liu has successfully developed and led multiple investigator-initiated and industry-sponsored phase 1 and 2 trials in GYN cancers, including early development of antibody-drug conjugates and combinations of PARP inhibitors with immuno-oncology agents. Her work has helped to establish the Dana-Farber GYN research program as a leading center for phase 1 and 2 trial development. Liu also serves as the associate clinical research officer for Dana-Farber. In presenting the award today, the National Cancer Institute stated, "Through her innovative clinical and translational research, Dr. Liu has advanced novel therapeutic strategies for ovarian and endometrial cancers, led practice-changing National Cancer Institute-sponsored clinical trials and championed the development of targeted therapies that have improved treatment options for patients worldwide." Liu's research focuses on identifying and validating novel therapies for gynecologic cancers, with an emphasis on rationally-designed, translationally-driven trials. Early in her career, she identified ErbB3 as a potential therapeutic target in ovarian cancer, leading to an international phase 2 trial of an ErbB3-directed antibody in conjunction with paclitaxel chemotherapy in recurrent platinum-resistant ovarian cancer. Dr. Liu also led the NCI-sponsored trial CTEP 8348 of combination cediranib and olaparib, which was the first trial to demonstrate the activity of combined anti-angiogenic and PARP inhibitor therapy in recurrent ovarian cancer. These results led to the NCI-sponsored international phase 3 NRG-GY004 trial comparing this combination to conventional chemotherapy in recurrent platinum-sensitive ovarian cancer, as well as CTEP 9825, a biomarker-driven phase 2 trial exploring potential biomarkers of sensitivity to this combination. Throughout her career, Liu has been an active member and leader within the NCI clinical trials network. Based upon work showing pre-clinical synergy between MEK inhibition and Bcl-xL inhibition in models of recurrent ovarian cancer, Liu developed and led CTEP 10597, a phase 1 trial testing the combination of cobimetinib with the Bcl-xL inhibitor pelcitoclax in recurrent ovarian and endometrial cancers, and she was an active contributor to CTEP 9525, a phase 1/2 study testing the combination of trametinib and navitoclax across solid tumors. Liu is also the current vice chair for the Ovarian Subcommittee of the NCI-funded NRG Oncology cooperative group. Liu is an active clinical trialist and is a principal investigator on multiple investigator-initiated and externally-sponsored interventional clinical studies in ovarian and endometrial cancer. She led the first trial demonstrating the clinical activity of WEE1 inhibition in uterine serous cancer and is a multi-PI of a P01 grant stemming from this work that is focused on understanding the role of replication stress in high-grade endometrial cancers. She also leads the Dana-Farber Gynecologic Oncology Division's translational modeling efforts and has developed panels of patient-derived xenograft and organoid models of ovarian and endometrial cancers that have provided insights into multiple novel therapeutic targets. Liu joins Panos Konstantinopoulos, MD, PhD (2022) and Geoff Shapiro, MD, PhD (2013) as Dana-Farber recipients of the Michaele C. Christian Oncology Drug Development Award. Gynecologic Cancer Related Doctors and Researchers Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Joyce F. Liu, MD, MPH

Dana-Farber Cancer Institute
Oct 9th, 2026
Seth Karp, MD, and Gavin Dunn MD, PhD, join Dana-Farber Cancer Institute.

Seth Karp, MD, and Gavin Dunn MD, PhD, join Dana-Farber Cancer Institute. Posted date October 9, 2026 This week, two distinguished leaders joined Dana-Farber Cancer Institute: Seth Karp, MD, began his new role as Chair of Surgery, and Gavin P. Dunn, MD, PhD, is now Neurosurgeon-in-Chief at the Institute. Dr. Karp also serves as Chair of the Roberta and Stephen R. Weiner Department of Surgery at Beth Israel Deaconess Medical Center (BIDMC), and will play a central role in the Dana-Farber Beth Israel Deaconess Cancer Collaboration, which will bring together world-class clinicians to deliver transformational, precision medicine in an environment solely dedicated to defying cancer. Dr. Dunn is the inaugural Chair of a new Department of Neurosurgery at Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians. As Neurosurgeon-in-Chief, he will work with clinical leaders at Dana-Farber on the coordination and delivery of neurosurgical services as part of multidisciplinary oncology care as part of Dana-Farber's clinical collaboration with BIDMC. "I am thrilled to welcome Seth Karp and Gavin Dunn, two highly respected leaders and researchers, to Dana-Farber," said Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber Cancer Institute. "Through our clinical collaboration with BIDMC, they will foster effective multidisciplinary care for patients and their families through world-class clinical services and innovation." Previously, Dr. Karp served as Chair of the Section of Surgical Sciences and System Surgeon-in-Chief at Vanderbilt University Medical Center. He was the H. William Scott Jr. Chair in Surgery and Professor of Surgery, Biomedical Ethics and Society, and Anesthesiology at Vanderbilt University School of Medicine. He joined the Vanderbilt faculty as Director of the Vanderbilt Transplant Center in 2011, and over the next 15 years, the Center became the largest in the United States. Dr. Karp is nationally known for his expertise in liver transplantation including the use of marginal grafts, and organ procurement and allocation. He has provided congressional testimony three times regarding national transplant policy. Dr. Karp has held numerous leadership positions in the American Society of Transplant Surgeons and the Organ Procurement and Transplantation Network and United Network for Organ Sharing (UNOS). He is former deputy editor of the American Journal of Transplantation, and a fellow of the American Surgical Association, American College of Surgeons, and Southern Surgical Association. Dr. Karp's clinical research interests include increasing the number of organs available for transplantation, improving organ procurement organization performance, and understanding and improving health for rural and underserved populations. His basic research examines the mechanisms of liver regeneration and treatment of monogenetic liver disease in children. Dr. Karp received his undergraduate degree in physics and astrophysics and his master's degree in astrophysics from Harvard University, and his medical degree from the joint Harvard/MIT program in health sciences and technology. He completed his residency at Brigham and Women's Hospital and transplant fellowship at The Johns Hopkins Hospital. Prior to joining Dana-Farber, Dr. Dunn served as Director of the Brain Tumor Immunology and Immunotherapy Program at Massachusetts General Hospital, where his clinical practice focused on caring for patients with primary and metastatic brain cancers, as well as general neurosurgical conditions. He is also a Professor of Neurosurgery at Harvard Medical School and a Captain in the United States Navy Reserves Medical Corps. Dr. Dunn is a Fellow and Member of the American Association of Neurological Surgeons, and a Member of the Congress of Neurological Surgeons and Society for Immunotherapy of Cancer. He also has served on the Board of Directors of the Society for Neuro-Oncology. Dr. Dunn's NIH-funded research focuses on understanding the immune response to brain tumors and the fundamental basis of CNS immunobiology. His work on the Brain Tumor Immunity cycle involves preclinical models and translational work that has resulted in the development of novel personalized cancer vaccine clinical studies. He is a co-chair of a clinical trial through the Alliance for Clinical Trials in Neuro-Oncology focused on recurrent glioblastoma. Dr. Dunn earned his undergraduate degree in molecular biology from Princeton University and his medical degree and PhD in immunology from Washington University in St. Louis. He completed his neurosurgery residency training at Massachusetts General Hospital and was a postdoctoral fellow with Executive Vice President & Chief Operating and Transformation Officer William C. Hahn, MD, PhD, at the Broad Institute and Dana-Farber Cancer Institute. Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Seth Karp, MD, Chair of Surgery Gavin P. Dunn, MD, PhD, Neurosurgeon-in-Chief

Healthcare Industry Today
Oct 7th, 2026
Upstage Lung Cancer presents Barry Manilow Tribute concert to support Lung Cancer research.

Upstage Lung Cancer presents Barry Manilow Tribute concert to support Lung Cancer research. Upstage Lung Cancer founder Hildy Grossman performs with fellow singers at a previous Upstage Lung Cancer benefit concert. Emmy Award-Winning Joyce Kulhawik Hosts Upstage Lung Cancer's 18th Annual Benefit Concert in Watertown, MA WATERTOWN, MA, UNITED STATES, October 7, 2026 / EINPresswire.com / - Upstage Lung Cancer (ULC), a nonprofit organization using the power of the performing arts to create awareness and fund lung cancer research, announces its 18th annual benefit concert, BARRY MANILOW: A Concert Tribute to a Master Showman. The live event takes place Tuesday, October 27, 2026, at 7:30 PM at the Mosesian Center for the Arts in Watertown, MA. Upstage Lung Cancer's 18th annual fall concert celebrates the music and legacy of Barry Manilow, Billboard's #1 Adult Contemporary Artist of all time. This year's benefit concert extends the urgent message that anyone with lungs can get lung cancer. In December 2025, doctors announced that they had found a stage-one cancerous tumor in Barry Manilow's left lung. Manilow said he never expected lung cancer would happen to him, but thanks to the early detection, his medical team was optimistic. "It's pure luck (and a great doctor) that it was found so early," Manilow said. This narrative is familiar to ULC founder and survivor Hildy Grossman, whose own cancer was found by accident. Upstage Lung Cancer's core mission is to ensure early detection is driven by accessible screening and innovative diagnostics, not by chance or accident. "Music has a unique ability to unite people around a shared cause," says Grossman. "Honoring Barry Manilow's timeless catalogue, while supporting lung cancer research, offers an evening of immense joy for a vital, life-saving purpose." The evening will be hosted by Emmy Award-winning arts and entertainment critic Joyce Kulhawik. Featured vocalists include acclaimed performers Brian De Lorenzo, Hildy Grossman of The Follen Angels, Michael Hammond of The Company Theatre, and Paula Markowicz of Divas With A Twist. Musical accompaniment will be provided by The Follen Angels band. The concert will also include the announcement of ULC's annual Fan Award to Bianca Bye and Leah Phillips, founders of the Young Lung Cancer Initiative. Other guests include Francine Jacobson, MD, MPH, thoracic radiologist, and Lauren Coye, young lung cancer survivor. About Upstage Lung Cancer Upstage Lung Cancer is a cancer advocacy organization that uses music and the performing arts to increase awareness, de-stigmatize lung cancer, and raise funds for early detection research. ULC founder, lung cancer survivor and jazz recording artist Hildy Grossman, lead singer of The Follen Angels, has combined her passion for music with her desire to foster knowledge about the leading cause of cancer death, with the goal of spotlighting new directions in lung cancer research and early detection. Over the past 20 years, Upstage Lung Cancer has funded more than $4.5 million in early detection research grants, investing in research opportunities. This year, grants were awarded to leading doctors at Massachusetts General Hospital, Boston Children's Hospital, and the Koch Institute at MIT. Upstage Lung Cancer maintains ongoing partnerships with LUNGevity Foundation, GO2 for Lung Cancer, Dana-Farber Cancer Institute, and Koch Institute at MIT. Ticket & Registration Information Proceeds support lung cancer research and early-detection initiatives. Date: Tuesday, October 27, 2026 Time: 7:30 PM EDT Location: Mosesian Center for the Arts, Watertown, MA Hildy Grossman Upstage Lung Cancer +1 617 835 9722 [email protected] Visit Healthcare Industry Today on social media: LinkedIn Instagram Facebook YouTube TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.